CN103479849A - Pharmaceutical composition for treating oyster herpes virus and preparation method thereof - Google Patents
Pharmaceutical composition for treating oyster herpes virus and preparation method thereof Download PDFInfo
- Publication number
- CN103479849A CN103479849A CN201310387106.7A CN201310387106A CN103479849A CN 103479849 A CN103479849 A CN 103479849A CN 201310387106 A CN201310387106 A CN 201310387106A CN 103479849 A CN103479849 A CN 103479849A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- weight
- radix polygoni
- effective ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating oyster herpes virus, which comprises the following traditional Chinese medicines in parts by weight: 15-30 parts of girald pteroxygonum root, 20-30 parts of geranium, 5-15 parts of folium artemisiae argyi, 10-25 parts of phellodendron bark, 2-10 parts of wild chrysanthemum flower and 5-15 parts of garlic. The invention also discloses a preparation method of the pharmaceutical composition. The girald pteroxygonum root, geranium and the like in the pharmaceutical composition have strong antiviral effect; and when the girald pteroxygonum root, geranium and the like are used as effective components, the pharmaceutical composition can well prevent and treat oyster herpes virus, and the effective rate is up to 99%.In the preparation method, the girald pteroxygonum root is extracted by a supercritical CO2 extraction process, so that the contents of the effective components (emodin and rheochrysidin) in the girald pteroxygonum root are higher. The preparation method is simple and easy to implement and suitable for large-scale production.
Description
Technical field
The present invention relates to treat the field of Chinese medicines of Concha Ostreae disease, be specifically related to a kind of pharmaceutical composition for the treatment of the oyster herpetovirus disease and preparation method thereof.
Background technology
The oyster herpetovirus particle is hexagon, diameter 70 ~ 90nm, tool monolayer adventitia, the dense nucleoid of some virion tools, infected Concha Ostreae digestive gland is grey Lycoperdon polymorphum Vitt, sporadic death, this disease often betides the Concha Ostreae of the hot water cultivation of discharging electric station, and the morbidity water temperature is 28 ~ 30 ℃, after water temperature descends, this disease disappears thereupon, and morbidity is closely related with water temperature.
Radix Polygoni Ciliinerve is the tuber of polygonaceae plant floating and thready pulse knotweed.All can gather the whole year, removes stem and leaf, fibrous root, cleans, cuts into slices and dry.Character identification, tuber is irregular bulk, or slightly cylindrical, long 8-15cm, or longer, diameter 3-7cm, surperficial brown color, slightly cylindrical, long 8-15cm, or longer, diameter 3-7cm, surperficial brown color.The root head has most stem foots to be the pimple shape.Matter is extremely hard, and difficulty fractures, the section buff.The root head has most stem foots to be the pimple shape.Matter is extremely hard, and difficulty fractures, the section buff.In the form of a ring, nearly marrow separately has the light yellow xylem bundle of dispersion to wooden depth yellow.Feeble QI, bitter in the mouth.
The Herba Erodii has a broad antifungal spectrum, its flavonoid has inhibitory action to multiple bacillus, lower than chlortetracycline, tetracycline, higher than berberine, Herba Andrographis, close with chloromycetin and streptomycin to the bacteriostasis of dysentery bacterium F1 strain; Its herb decoct also has obvious inhibitory action to staphylococcus aureus, group B streptococcus, streptococcus pneumoniae, micrococcus catarrhalis.This product herb decoct all has obvious inhibitory action to the 68-1 of the section strain of influenza A virus capital, Asia and the celestial platform strain of parainfluenza virus work type and herpes simplex virus.Herba Erodii tannin and catabolite corilagin thereof have stronger active anticancer, to carcinogen benzopyrene-7, and 8-glycol-9, the mutagenic processes of 10-epoxide has strong inhibitory action.
Summary of the invention
Goal of the invention: in order to overcome the deficiencies in the prior art, the invention provides a kind of pharmaceutical composition for the treatment of the oyster herpetovirus disease and preparation method thereof.
Technical scheme: in order to solve the problems of the technologies described above, the invention provides a kind of pharmaceutical composition for the treatment of the oyster herpetovirus disease, comprise following Chinese medicine, its parts by weight are respectively: 15 ~ 30 parts of Radix Polygoni Ciliinerves, 20 ~ 30 parts of Herba Erodiis, 5 ~ 15 parts of Folium Artemisiae Argyis, 10 ~ 25 parts of Cortex Phellodendris, 2 ~ 10 parts of Flos Chrysanthemi Indicis, 5 ~ 15 parts, Bulbus Allii.
Preferably, its parts by weight are respectively: 20 ~ 30 parts of Radix Polygoni Ciliinerves, 25 ~ 30 parts of Herba Erodiis, 10 ~ 15 parts of Folium Artemisiae Argyis, 15 ~ 25 parts of Cortex Phellodendris, 6 ~ 10 parts of Flos Chrysanthemi Indicis, 10 ~ 15 parts, Bulbus Allii.
More preferably, its parts by weight are respectively: 20 parts of Radix Polygoni Ciliinerves, 25 parts of Herba Erodiis, 10 parts of Folium Artemisiae Argyis, 15 parts of Cortex Phellodendris, 6 parts of Flos Chrysanthemi Indicis, 10 parts, Bulbus Allii.
The preparation method of described pharmaceutical composition comprises the following steps:
1) Radix Polygoni Ciliinerve taken by above-mentioned parts by weight adds 80% ethanol of 10 ~ 15 times of amounts of its weight, adopts supercritical CO
2extraction obtains the Radix Polygoni Ciliinerve effective ingredient;
2) take Herba Erodii by above-mentioned parts by weight and add 75% ethanol of 10 ~ 15 times of amounts of its weight to carry out alcohol reflux, extract 3 times, each 2.5h obtains the Herba Erodii effective ingredient;
3) take Folium Artemisiae Argyi, Cortex Phellodendri, Flos Chrysanthemi Indici, Bulbus Allii by above-mentioned parts by weight and add 20 ~ 25 times of decoctings of Folium Artemisiae Argyi, Cortex Phellodendri, Flos Chrysanthemi Indici, Bulbus Allii gross weight to boil 2 ~ 4h, filter, obtain supernatant;
4) by Radix Polygoni Ciliinerve effective ingredient, the step 2 of step 1)) Herba Erodii effective ingredient and the supernatant of step 3) mix the pharmaceutical composition of the oyster herpetovirus disease that obtains medical treatment.
The effective ingredient of described Radix Polygoni Ciliinerve is 9,10-Anthracenedione,1,3,8-thihydroxy-6-methyl and physcion.
Described Herba Erodii effective ingredient is p-sitosterol, Quercetin, kaempferol-7-0-rhamnoside, kaempferol and gallic acid.
Described supercritical CO
2extraction conditions is: 50 ~ 60 ℃ of temperature, pressure are that 27 ~ 30MPa, quiet hour are 2h, and dynamic time is 1.5h.
Beneficial effect: a kind of pharmaceutical composition for the treatment of the oyster herpetovirus disease provided by the invention, wherein Radix Polygoni Ciliinerve, Herba Erodii etc. all have very strong antiviral effect, these can prevent well and treat the oyster herpetovirus disease as effective ingredient, and treated effect is up to 99%.In preparation method of the present invention, Radix Polygoni Ciliinerve extracts and has adopted supercritical CO
2extracting method, make the 9,10-Anthracenedione,1,3,8-thihydroxy-6-methyl of Radix Polygoni Ciliinerve effective ingredient and physcion content higher.Simple, the applicable large-scale production of preparation method of the present invention.
The specific embodiment
Below in conjunction with embodiment, the present invention is further described.
embodiment 1:
A kind of pharmaceutical composition for the treatment of the oyster herpetovirus disease, comprise following Chinese medicine, and its parts by weight are respectively: 15 parts of Radix Polygoni Ciliinerves, 20 parts of Herba Erodiis, 5 parts of Folium Artemisiae Argyis, 10 parts of Cortex Phellodendris, 2 parts of Flos Chrysanthemi Indicis, 5 parts, Bulbus Allii.
The preparation method of described pharmaceutical composition comprises the following steps:
1) Radix Polygoni Ciliinerve taken by above-mentioned parts by weight adds 80% ethanol of 10 times of amounts of its weight, adopts supercritical CO
2extraction obtains the Radix Polygoni Ciliinerve effective ingredient;
2) take Herba Erodii by above-mentioned parts by weight and add 75% ethanol of 10 times of amounts of its weight to carry out alcohol reflux, extract 3 times, each 2.5h obtains the Herba Erodii effective ingredient;
3) take Folium Artemisiae Argyi, Cortex Phellodendri, Flos Chrysanthemi Indici, Bulbus Allii by above-mentioned parts by weight and add 20 times of decoctings of Folium Artemisiae Argyi, Cortex Phellodendri, Flos Chrysanthemi Indici, Bulbus Allii gross weight to boil 2h, filter, obtain supernatant;
4) by Radix Polygoni Ciliinerve effective ingredient, the step 2 of step 1)) Herba Erodii effective ingredient and the supernatant of step 3) mix the pharmaceutical composition of the oyster herpetovirus disease that obtains medical treatment.
The effective ingredient of described Radix Polygoni Ciliinerve is 9,10-Anthracenedione,1,3,8-thihydroxy-6-methyl and physcion.
Described Herba Erodii effective ingredient is p-sitosterol, Quercetin, kaempferol-7-0-rhamnoside, kaempferol and gallic acid.
Described supercritical CO
2extraction conditions is: temperature 50 C, pressure are that 27MPa, quiet hour are 2h, and dynamic time is 1.5h.
embodiment 2:
A kind of pharmaceutical composition for the treatment of the oyster herpetovirus disease, comprise following Chinese medicine, and its parts by weight are respectively: 30 parts of Radix Polygoni Ciliinerves, 30 parts of Herba Erodiis, 15 parts of Folium Artemisiae Argyis, 25 parts of Cortex Phellodendris, 10 parts of Flos Chrysanthemi Indicis, 15 parts, Bulbus Allii.
The preparation method of described pharmaceutical composition comprises the following steps:
1) Radix Polygoni Ciliinerve taken by above-mentioned parts by weight adds 80% ethanol of 15 times of amounts of its weight, adopts supercritical CO
2extraction obtains the Radix Polygoni Ciliinerve effective ingredient;
2) take Herba Erodii by above-mentioned parts by weight and add 75% ethanol of 15 times of amounts of its weight to carry out alcohol reflux, extract 3 times, each 2.5h obtains the Herba Erodii effective ingredient;
3) take Folium Artemisiae Argyi, Cortex Phellodendri, Flos Chrysanthemi Indici, Bulbus Allii by above-mentioned parts by weight and add 25 times of decoctings of Folium Artemisiae Argyi, Cortex Phellodendri, Flos Chrysanthemi Indici, Bulbus Allii gross weight to boil 4h, filter, obtain supernatant;
4) by Radix Polygoni Ciliinerve effective ingredient, the step 2 of step 1)) Herba Erodii effective ingredient and the supernatant of step 3) mix the pharmaceutical composition of the oyster herpetovirus disease that obtains medical treatment.
The effective ingredient of described Radix Polygoni Ciliinerve is 9,10-Anthracenedione,1,3,8-thihydroxy-6-methyl and physcion.
Described Herba Erodii effective ingredient is p-sitosterol, Quercetin, kaempferol-7-0-rhamnoside, kaempferol and gallic acid.
Described supercritical CO
2extraction conditions is: temperature 60 C, pressure are that 30MPa, quiet hour are 2h, and dynamic time is 1.5h.
embodiment 3:
A kind of pharmaceutical composition for the treatment of the oyster herpetovirus disease, comprise following Chinese medicine, and its parts by weight are respectively: its parts by weight are respectively: 20 parts of Radix Polygoni Ciliinerves, 25 parts of Herba Erodiis, 10 parts of Folium Artemisiae Argyis, 15 parts of Cortex Phellodendris, 6 parts of Flos Chrysanthemi Indicis, 10 parts, Bulbus Allii.
The preparation method of described pharmaceutical composition comprises the following steps:
1) Radix Polygoni Ciliinerve taken by above-mentioned parts by weight adds 80% ethanol of 12 times of amounts of its weight, adopts supercritical CO
2extraction obtains the Radix Polygoni Ciliinerve effective ingredient;
2) take Herba Erodii by above-mentioned parts by weight and add 75% ethanol of 12 times of amounts of its weight to carry out alcohol reflux, extract 3 times, each 2.5h obtains the Herba Erodii effective ingredient;
3) take Folium Artemisiae Argyi, Cortex Phellodendri, Flos Chrysanthemi Indici, Bulbus Allii by above-mentioned parts by weight and add 23 times of decoctings of Folium Artemisiae Argyi, Cortex Phellodendri, Flos Chrysanthemi Indici, Bulbus Allii gross weight to boil 3h, filter, obtain supernatant;
4) by Radix Polygoni Ciliinerve effective ingredient, the step 2 of step 1)) Herba Erodii effective ingredient and the supernatant of step 3) mix the pharmaceutical composition of the oyster herpetovirus disease that obtains medical treatment.
The effective ingredient of described Radix Polygoni Ciliinerve is 9,10-Anthracenedione,1,3,8-thihydroxy-6-methyl and physcion.
Described Herba Erodii effective ingredient is p-sitosterol, Quercetin, kaempferol-7-0-rhamnoside, kaempferol and gallic acid.
Described supercritical CO
2extraction conditions is: 56 ℃ of temperature, pressure are that 28MPa, quiet hour are 2h, and dynamic time is 1.5h.
Concha Ostreae in the present invention adopts to hang down forms the shed frame type cultivation method oyster culture in method, and this method mariculture area requires trend unimpeded, and flow velocity 20-25 cel has appropriate fresh water to inject, and the suitable Concha Ostreaes of physical and chemical factor such as sea area food organisms, water temperature, salinity are formed.The zone that culturing area can keep the 2-3 rice depth of water while being chosen in low tidal region or neap flood, seawater transparency is more than 0.5 meter, and painting face is smooth, can not be excessively soft, being coated with matter is sandy or argillo arenaceous.Frame is two row or stub (Phyllostachys pubescens Mazei ex H.de Lebaie corresponding to multirow, Shi Junke) and the polyethylene rope of horizontal laying (or Phyllostachys pubescens Mazei ex H.de Lebaie) form, the capable following current of stake arranges, in the stake row, two pilespacings are from being 3-4 rice, relative distance between row and row is 1 meter left and right, the stake line length is determined the length of stake according to the cultivation place, be generally 3 meters, also by beach substrate soft or hard, determined, the pile crown major part is vertically squeezed in painting, beach face 0.6-0.8 rice is exposed in upper end, top at pile crown, polyethylene rope or the Phyllostachys pubescens Mazei ex H.de Lebaie above with 240 (thighs) are concatenated stake by row, the two ends of stake row are fixed polyethylene rope with taper pile, form a fixing low frame.40-45 days after collecting seedling, after collecting seedling and reaching production requirement, the collector that will adopt the spat of oyster disperses, and moves on on the frame of low tidal region and forms.The two ends of oyster shell collector are hung respectively on the polyethylene rope or Phyllostachys pubescens Mazei ex H.de Lebaie of cultivation frame, and the flat extension of Seedling string slightly is parabolic type, between string and string apart from 20-25 centimetre, and parallel keeping hanging, Seedling string minimum point is be 20 centimetres away from beach face more than.
The embodiment of the present invention 1 ~ 3 any one pharmaceutical composition usage and consumption: the sick burst period of oyster herpetovirus, to shed frame type oyster culture zone, splash comprehensively, every 1 cubic metre of water body medication 1.3 ~ 2.7g, every mu of pharmaceutical composition 1600 ~ 1800g of the present invention for water body depth of water 1m, be used in conjunction 3 days.
Experimental condition:
Category-A oyster culture zone: 1 mu of area, 1.7 meters of water depths, water source is that Yangtze River Water, pH are 7.0, water temperature is 25 ℃.100 of this zone Concha Ostreaes, average weight are 83g.
Category-B oyster culture zone: 0.9 mu of area, 1.6 meters of water depths, water source is that Yangtze River Water, pH are 7.0, water temperature is 25 ℃.100 of this pond Concha Ostreaes, average weight are 82g.
Test method:
Category-A oyster culture zone medication 1.8kg, first day is 1 Concha Ostreae in the dust, second day medication 1.8kg, oyster herpetovirus is sick to be improved, the 3rd day medication 1.8kg, oyster herpetovirus is sick cures, and movable and feed recovers normal condition.
Category-B oyster culture zone does not have medication, and first day is 16 Concha Ostreaes in the dust, 34 in the dust of second days, the 3rd day 50 in the dust.
Result of the test:
Category-A oyster culture zone is 1 oyster herpetovirus disease in the dust, and cure rate is 99%, the not medication of category-B oyster culture zone, and mortality rate increases, last all dead.
The above is only the preferred embodiment of the present invention; be noted that for those skilled in the art; under the premise without departing from the principles of the invention, can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.
Claims (7)
1. a pharmaceutical composition for the treatment of the oyster herpetovirus disease, it is characterized in that, comprise following Chinese medicine, its parts by weight are respectively: 15 ~ 30 parts of Radix Polygoni Ciliinerves, 20 ~ 30 parts of Herba Erodiis, 5 ~ 15 parts of Folium Artemisiae Argyis, 10 ~ 25 parts of Cortex Phellodendris, 2 ~ 10 parts of Flos Chrysanthemi Indicis, 5 ~ 15 parts, Bulbus Allii.
2. the pharmaceutical composition for the treatment of oyster herpetovirus disease according to claim 1, it is characterized in that, comprise following Chinese medicine, its parts by weight are respectively: 20 ~ 30 parts of Radix Polygoni Ciliinerves, 25 ~ 30 parts of Herba Erodiis, 10 ~ 15 parts of Folium Artemisiae Argyis, 15 ~ 25 parts of Cortex Phellodendris, 6 ~ 10 parts of Flos Chrysanthemi Indicis, 10 ~ 15 parts, Bulbus Allii.
3. the pharmaceutical composition for the treatment of oyster herpetovirus disease according to claim 1, is characterized in that, comprises following Chinese medicine, and its parts by weight are respectively: 20 parts of Radix Polygoni Ciliinerves, 25 parts of Herba Erodiis, 10 parts of Folium Artemisiae Argyis, 15 parts of Cortex Phellodendris, 6 parts of Flos Chrysanthemi Indicis, 10 parts, Bulbus Allii.
4. the preparation method of the described pharmaceutical composition of claim 1 ~ 3 any one, is characterized in that, comprises the following steps:
1) Radix Polygoni Ciliinerve taken by above-mentioned parts by weight adds 80% ethanol of 10 ~ 15 times of amounts of its weight, adopts supercritical CO
2extraction obtains the Radix Polygoni Ciliinerve effective ingredient;
2) take Herba Erodii by above-mentioned parts by weight and add 75% ethanol of 10 ~ 15 times of amounts of its weight to carry out alcohol reflux, extract 3 times, each 2.5h obtains the Herba Erodii effective ingredient;
3) take Folium Artemisiae Argyi, Cortex Phellodendri, Flos Chrysanthemi Indici, Bulbus Allii by above-mentioned parts by weight and add 20 ~ 25 times of decoctings of Folium Artemisiae Argyi, Cortex Phellodendri, Flos Chrysanthemi Indici, Bulbus Allii gross weight to boil 2 ~ 4h, filter, obtain supernatant;
4) by Radix Polygoni Ciliinerve effective ingredient, the step 2 of step 1)) Herba Erodii effective ingredient and the supernatant of step 3) mix the pharmaceutical composition of the oyster herpetovirus disease that obtains medical treatment.
5. the preparation method of pharmaceutical composition according to claim 4, is characterized in that, the effective ingredient of described Radix Polygoni Ciliinerve is 9,10-Anthracenedione,1,3,8-thihydroxy-6-methyl and physcion.
6. the preparation method of pharmaceutical composition according to claim 4, is characterized in that, described Herba Erodii effective ingredient is p-sitosterol, Quercetin, kaempferol-7-0-rhamnoside, kaempferol and gallic acid.
7. the preparation method of pharmaceutical composition according to claim 4, is characterized in that, described supercritical CO
2extraction conditions is: 50 ~ 60 ℃ of temperature, pressure are that 27 ~ 30MPa, quiet hour are 2h, and dynamic time is 1.5h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310387106.7A CN103479849B (en) | 2013-08-30 | 2013-08-30 | A kind ofly treat pharmaceutical composition of oyster herpetovirus disease and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310387106.7A CN103479849B (en) | 2013-08-30 | 2013-08-30 | A kind ofly treat pharmaceutical composition of oyster herpetovirus disease and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103479849A true CN103479849A (en) | 2014-01-01 |
| CN103479849B CN103479849B (en) | 2015-10-14 |
Family
ID=49820662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310387106.7A Active CN103479849B (en) | 2013-08-30 | 2013-08-30 | A kind ofly treat pharmaceutical composition of oyster herpetovirus disease and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103479849B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6475426A (en) * | 1987-09-17 | 1989-03-22 | Nisshin Flour Milling Co | Prophylactic and remedy for streptococcal infection in fishes |
| CN102552502A (en) * | 2012-01-11 | 2012-07-11 | 河南天纳图生物科技有限公司 | Traditional Chinese medicine for treating bacterial diseases in poultry |
| CN102727503A (en) * | 2011-04-13 | 2012-10-17 | 东北林业大学 | Application of Geraniin extracted from Geranium sibiricum Linne in preparation of anti-herpes virus medicaments |
| CN103127310A (en) * | 2011-12-05 | 2013-06-05 | 蔡丽莎 | Drug for curing measles |
-
2013
- 2013-08-30 CN CN201310387106.7A patent/CN103479849B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6475426A (en) * | 1987-09-17 | 1989-03-22 | Nisshin Flour Milling Co | Prophylactic and remedy for streptococcal infection in fishes |
| CN102727503A (en) * | 2011-04-13 | 2012-10-17 | 东北林业大学 | Application of Geraniin extracted from Geranium sibiricum Linne in preparation of anti-herpes virus medicaments |
| CN103127310A (en) * | 2011-12-05 | 2013-06-05 | 蔡丽莎 | Drug for curing measles |
| CN102552502A (en) * | 2012-01-11 | 2012-07-11 | 河南天纳图生物科技有限公司 | Traditional Chinese medicine for treating bacterial diseases in poultry |
Non-Patent Citations (4)
| Title |
|---|
| 周燕园等: "中药抗单纯疱疹病毒的实验研究概况", 《广西中医药》 * |
| 杨先乐等: "《水产养殖用药处方大全》", 31 July 2008, 化学工业出版社 * |
| 王勇强等: "中草药用于水产养殖病害防治的研究与应用", 《齐鲁渔业》 * |
| 王育良等: "中药抗单纯疱疹病毒的实验研究", 《中国中医眼科杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103479849B (en) | 2015-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104115999A (en) | Chinese herbal medicine feed additive and feed containing additive | |
| CN103877206A (en) | Compound Chinese herbal medicine for promoting growth of yellow catfish, and preparation method thereof | |
| CN102771279A (en) | Prevention and treatment method of edible lily anthracnose | |
| CN104758802A (en) | Chinese medicinal composition for treatment of Mylopharyngodon piceus bacterial enteritis | |
| CN104873434A (en) | Pure-natural olive leaf essence shampoo and production process thereof | |
| CN104441141A (en) | Mildew-proof and insect-proof wickerwork treating agent | |
| CN103479849B (en) | A kind ofly treat pharmaceutical composition of oyster herpetovirus disease and preparation method thereof | |
| CN106234454A (en) | A kind of Chinese herbal medicine pesticide of Oryza sativa L. and preparation method thereof | |
| CN103877458A (en) | Compound Chinese herbal medicine for promoting lutjanus sanguineus growth and preparation method thereof | |
| CN104724833A (en) | Method for killing blue-green algae to purify water | |
| CN107155961A (en) | A kind of Spinibarbus sinensis ecological cultivation method | |
| Sun et al. | Astragalus and Chrysanthemum for sustainable life | |
| CN105994386B (en) | A kind of mahonia bealei extract and preparation method thereof and the application in resisting tobacco black shank | |
| CN104584813A (en) | Propagation method of Amorphophallus rivieri Durieu slices treated by Chinese medicinal formula | |
| CN109125540A (en) | A kind of ageratum oral liquid and preparation method thereof for preventing and treating bird flu | |
| CN104970049A (en) | Disinfection method for domestic fungus culture room | |
| CN103006805A (en) | Method for pink eye disease treatment by using traditional Chinese medicine | |
| CN109731085B (en) | External lotion product and preparation method thereof | |
| CN105456836A (en) | Traditional Chinese medicine formula for treating psoriasis | |
| CN104996498A (en) | Non-polluting Chinese herb insecticide | |
| CN105561063A (en) | Traditional Chinese medicine formula for treating damp-heat congesting and exuberant type nephropathy | |
| CN105561153A (en) | Traditional Chinese medicine formula for treatment of suppurative cholecystitis | |
| CN104441140A (en) | Wicker treating agent | |
| CN104381342A (en) | Environment-friendly biological pesticide | |
| CN103947802A (en) | Herbal tea for clearing away heat and toxic materials |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |